Bernstein lowered the firm’s price target on Medline (MDLN) to $54 from $56 and keeps an Outperform rating on the shares following quarterly results. The firm notes that companies are not supposed to miss in their first full quarter after an IPO, and Medline shares plunged. Bernstein sees no change to fundamentals.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLN:
- Medline price target lowered to $55 from $60 at Citi
- Medline Maintained at Buy as Analyst Trims Price Target to $53 on Margin Pressures but Highlights Strong Growth Outlook
- Medline reports Q1 adjusted EPS 33c, consensus 29c
- Medline backs FY26 adjusted EBITDA view $3.5B-$3.6B
- Medline issued recall of all neuro sponge products, FDA says